Cargando…
Reduction of In-Stent Restenosis and Inflammation with One Stent: New Concept of Sirolimus and Ascorbic Acid-Eluting Coronary Stent
Autores principales: | Ryu, JiWung, Kim, Jung-Sun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Cardiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636760/ https://www.ncbi.nlm.nih.gov/pubmed/34854581 http://dx.doi.org/10.4070/kcj.2021.0336 |
Ejemplares similares
-
Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011) -
Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014) -
Multiple Sequential Complications After Sirolimus-Eluting Stent Implantation: Very Late Stent Thrombosis, Stent Fracture, In-Stent Restenosis, and Peri-Stent Aneurysm
por: Seol, Sang-Hoon, et al.
Publicado: (2009) -
Sirolimus-eluting coronary stents: a review
por: Abizaid, Alexandre
Publicado: (2007) -
Early Restenosis of Sirolimus-eluting Stent: An Unusual Case of a Hyperthyroid Patient
por: Shabbir, Syeda Javeria, et al.
Publicado: (2019)